多发性硬化症免疫发病机制与免疫治疗的最新进展
Update on immunopathogenesis and immunotherapy in multiple sclerosis.
作者信息
Selter Rebecca C, Hemmer Bernhard
机构信息
Department of Neurology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.
Department of Neurology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; Competence Network on Multiple Sklerosis, Munich, Germany.
出版信息
Immunotargets Ther. 2013 Apr 25;2:21-30. doi: 10.2147/ITT.S31813. eCollection 2013.
Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system. Both genetic and environmental factors are believed to contribute to the pathogenesis of the disease. Histopathological findings suggest that multiple sclerosis is an immune-mediated disease, involving both the cellular and humoral immune systems. Within the last 20 years, several disease-modifying therapies for the treatment of multiple sclerosis were established. Moreover, promising new substances are currently being tested in clinical trials and will likely broaden the therapeutic opportunities available within the upcoming years.
多发性硬化症是一种中枢神经系统的慢性炎性脱髓鞘疾病。遗传因素和环境因素均被认为与该疾病的发病机制有关。组织病理学研究结果表明，多发性硬化症是一种免疫介导的疾病，涉及细胞免疫系统和体液免疫系统。在过去20年里，已确立了几种用于治疗多发性硬化症的疾病修正疗法。此外，目前有前景的新物质正在临床试验中进行测试，很可能在未来几年扩大可用的治疗选择。
Zotero 插件